- CEO Morhet to Discuss Continued Expansion of DXL(TM) Patent Protection
7th Annual BIO Investor Forum -
BRITISH COLUMBIA, Canada, Oct. 30 /CNW/ -- InNexus Biotechnology Inc.,
(OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug
development company commercializing the next generation of monoclonal
antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announced
today that it has received patent grants in Germany, Spain, France, Great
Britain and Italy further expanding patent protection of its DXL(TM)
technology in Europe. The patents, titled "METHOD OF AFFINITY CROSS-LINKING
BIOLOGICALLY ACTIVE, IMMUNOGENIC PEPTIDES TO ANTIBODIES," relate to the
Company's ability to create, develop and manufacture antibodies based on its
DXL(TM) technology platform. The new patents name InNexus scientists as
inventors and are solely owned by InNexus.
"These patent grants demonstrate our commitment to providing real value
to our shareholders by protecting and ensuring exclusivity of our DXL(TM)
technology. Our patent portfolio provides potential for future royalty and
licensing deals or outright sales of our expanding and maturing family of
DXL(TM) preclinical candidates," said Jeff Morhet, Chairman and CEO of
InNexus. "Patents are the currency of our industry and these patent grants
also provide InNexus with additional tools to prevent others from making,
using and selling DXL(TM) antibodies."
CEO Morhet will present at the 7th Annual BIO Investor Forum on October
30, 2008 and his thirty-minute presentation to potential investors and
industry partners will begin at 3:15PM within the Twin Peaks South Room of the
Palace Hotel in San Francisco, California. He will provide a company
overview, including information about InNexus' unique business strategy, its
DXL(TM) technology platform, partnerships, company milestones and the recent
European patent grants.
InNexus is a drug development company commercializing the next generation
of monoclonal antibodies based on its DXL(TM) technology, which improves the
potency of existing antibody products while opening new markets and disease
applications. DXL(TM) antibodies utilize unique, novel and patented methods
and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-
house developmental facilities. These development resources provide validation
of protein and peptide discoveries, enabling InNexus (and its strategic
partners) to advance novel drug therapeutics and diagnostics. To learn more
about InNexus, please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This news
release may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control, that may cause actual
results or performance to differ materially from those currently anticipated
in such statements.
For further information:
For further information: Wade Brooksby, Chief Financial Officer of
InNexus Biotechnology Inc., +1-480-862-7500 Web Site: http://www.ixsbio.com